We reported that core biomarkers changed with disease severity both in clinical diagnosis and clinico-pathological groups, with stepwise increases of p-tau217, NfL and GFAP, and a decrease of plasma Aβ42/40, from CU to dementia. The gene discussed is GFAP; the disease is dementia.